[Effects of Panax notoginseng saponins on ACE2 and TNF-alpha in rats with post-myocardial infarction-ventricular remodeling].
OBJECTIVE
To research the effects of Panax notoginseng saponins (PNS) on angiotensin-converting enzymes 2 ( ACE2) and tumor necrosis factor-alpha (TNF-alpha) in rats with post-myocardial infarction ventricular remodeling.


METHODS
Models of acute myocardial infarction (AMI) were produced by ligation of left anterior descending coronary artery, 24 hours after operation the rats were randomly divided into control and experiment groups, then respectively administrated with NS, fosinopril and low, middle and high dosage of PNS for four consecutive weeks. To observe effects of PNS on malondialdehyde (MDA), nitric oxide (NO), glutathione peroxidase (GSH-Px), ACE2 and TNF-alpha in rats with post-myocardial infarction ventricular remodeling.


RESULTS
Compared with NS group, MDA significantly decreased, the activity of GSH-Px significantly increased (P < 0.05 or P < 0.01), NO of the high-dose PNS group decreased (P < 0.05), Compared with the NS group, ACE2 increased and TNF-a significantly decreased in low-dose PNS group, middle and high-dose groups (P < 0.05).


CONCLUSIONS
PNS can stimulate ACE2 to inhibit the expression of TNF-alpha and enhance the antioxidance. PNS can reduce pathological injury of cardiac myocytes in myocardial ischemia and cardiac muscle, which can improve ventricular remodeling.
Guo
Jie-Wen
JW
Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou 510130, China. guo774@sina.com
Li
Li-Ming
LM
Qiu
Guang-Qing
GQ
Deng
Zhi-Jun
ZJ
Fu
Yong-Heng
YH
Yang
Min
M
Pan
Jing-Qiang
JQ
Liu
Ruo-Xuan
RX
D000085962:Angiotensin-Converting Enzyme 2; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D017328:Fosinopril / Q000494:pharmacology; D005979:Glutathione Peroxidase / Q000097:blood / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000097:blood / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009569:Nitric Oxide / Q000097:blood / Q000378:metabolism; D053723:Panax notoginseng / Q000737:chemistry; D007703:Peptidyl-Dipeptidase A / Q000097:blood* / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood* / Q000378:metabolism; D020257:Ventricular Remodeling / Q000187:drug effects*
D000975:Antioxidants; D012503:Saponins; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D008315:Malondialdehyde; D005979:Glutathione Peroxidase; D007703:Peptidyl-Dipeptidase A; C000705329:Ace2 protein, rat; D000085962:Angiotensin-Converting Enzyme 2; D017328:Fosinopril